Eliakim, Rami

Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders

Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis

Inflammatory Bowel DiseaseMicroscopic Colitis

Cited by 1,910

Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management

Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis

Inflammatory Bowel DiseaseOcular Diseases and Behçet’s Syndrome

Cited by 1,180

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget

Pancreatic and Hepatic Oncology ResearchRNA Interference and Gene Delivery

Cited by 336

Mutant KRAS is a druggable target for pancreatic cancer

Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences

RNA Interference and Gene DeliveryPancreatic and Hepatic Oncology Research

Cited by 295

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

Ungar, B., Kopylov, U., Engel, T., Yavzori, M., Fudim, E., Picard, O., Lang, A., Williet, N., Paul, S., Chowers, Y., et al. (2017) · Alimentary Pharmacology & Therapeutics

Inflammatory Bowel DiseaseBiosimilars and Bioanalytical Methods

Cited by 118